Medical Devices Europe

Europe Preeclampsia Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Preeclampsia Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $269.7 Mn Placeholder estimate
Estimate 2025 $285.6 Mn 17.8% of the global market
Projected 2034 $478.5 Mn 67.5% Adds $192.9 Mn over 9 forecast years
CAGR 2025–2034 5.9% Faster than 32% of 173 Medical Devices markets here
Key players 5
  • Europe is 17.82% of the global market.
  • Among regions, the largest is North America at $725.3 Mn.
  • Fastest growing: APAC at 8.7% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$192.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Preeclampsia Diagnostics Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $269.7 Mn — —
2025 (base) $285.6 Mn +$15.9 Mn —
2026 (forecast) $302.5 Mn +$16.9 Mn +5.9%
2027 (forecast) $320.3 Mn +$17.8 Mn +12.1%
2028 (forecast) $339.2 Mn +$18.9 Mn +18.8%
2029 (forecast) $359.3 Mn +$20.0 Mn +25.8%
2030 (forecast) $380.5 Mn +$21.2 Mn +33.2%
2031 (forecast) $402.9 Mn +$22.4 Mn +41.1%
2032 (forecast) $426.7 Mn +$23.8 Mn +49.4%
2033 (forecast) $451.8 Mn +$25.2 Mn +58.2%
2034 (forecast) $478.5 Mn +$26.7 Mn +67.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Preeclampsia Diagnostics Market Analysis at a glance
Market size, 2025$285.6 Mn placeholder estimate
Forecast, 2034$478.5 Mn placeholder estimate
Growth (CAGR), 2025–20345.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, use and end user (see all)
Key playersRoche Diagnostics, Thermo Fisher Scientific Inc., Perkin Elmer, Siemens Healthineers, Quidel Corporation (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
Active clinical trials45 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Preeclampsia Diagnostics Market Analysis Executive Summary

Preeclampsia diagnostics are blood tests and monitoring tools that predict or detect dangerous high blood pressure in pregnancy.

Key segments of the preeclampsia Diagnostics market include test (sFlt-1/PlGF Ratio Tests, PlGF Tests and Blood Pressure Monitoring) and use (Screening, Diagnosis and Prognosis).

Bar chart: Europe Preeclampsia Diagnostics market size, 2024–2034, placeholder estimates. $269.7 Mn in 2024, $285.6 Mn in 2025 and $478.5 Mn in 2034, 5.9% CAGR.
Europe Preeclampsia Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Preeclampsia Diagnostics Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the preeclampsia Diagnostics market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the preeclampsia Diagnostics market.

Competitive Landscape for Preeclampsia Diagnostics Market in Europe

The preeclampsia Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Preeclampsia Diagnostics Market in Europe

Preeclampsia Diagnostics in Europe: rules, payment and research

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 45 studies on Preeclampsia Diagnostics that are recruiting, active or about to start in Europe.⁠[9]

[1] European Commission, medical devices. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Ministry of Health. Checked 14 Nov 2026.

[5] Roszdravnadzor. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how preeclampsia Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Preeclampsia Diagnostics right now, from free public sources.

Clinical trials

45 active trials in UK, Germany, France, Italy, Spain and Russia

Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Preeclampsia Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Preeclampsia Diagnostics market in Europe?
Placeholder estimate: about $285.6 Mn in 2025, rising to about $478.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Preeclampsia Diagnostics market in Europe growing?
Placeholder estimate: about 5.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Preeclampsia Diagnostics market report cover?
The report splits the market by test (sFlt-1/PlGF Ratio Tests, PlGF Tests, Blood Pressure Monitoring, Urine Protein Tests), use (Screening, Diagnosis, Prognosis) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Preeclampsia Diagnostics market?
Key players include Roche Diagnostics, Thermo Fisher Scientific Inc., Perkin Elmer, Siemens Healthineers and Quidel Corporation.
What is driving the Preeclampsia Diagnostics market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Who regulates Preeclampsia Diagnostics in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Preeclampsia Diagnostics are running in Europe?
45 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Preeclampsia Diagnostics?
PubMed lists 7,556 papers on Preeclampsia Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on maternal and diagnostics and lab testing

See the topic